

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

FRESENIUS KABI USA, LLC,
Petitioner,

v.

CEPHALON, INC.,
Patent Owner.

Case IPR2016-00111
Patent No. 8,895,756 B2

PATENT OWNER'S UPDATED EXHIBIT LIST

PATENT OWNER'S UPDATED EXHIBIT LIST

EXHIBIT	DESCRIPTION
2001	TREANDA® Prescribing Information
2002	“Treanda New Drug Application for the Treatment of Chronic Lymphocytic Leukemia Granted Priority Review Status by FDA,” <i>Drugs.com</i> (December 3, 2007)
2003	File History of U.S. Patent No. 8,609,863
2004	“FDA Approves Treanda,” <i>Drugs.com</i> (March 20, 2008)
2005	“Cephalon Receives FDA Approval for Treanda to Treat Patients with Relapsed Indolent Non-Hodgkin’s Lymphoma,” <i>Drugs.com</i> (October 31, 2008)
2006	Brad S. Kahl, et al., “Bendamustine Is Effective Therapy in Patients with Rituximab-Refractory, Indolent B-cell Non-Hodgkin Lymphoma: Results From a Multicenter Study,” <i>Cancer</i> 106 (January 1, 2010)
2007	K. Sue Robinson, et al., “Phase II Multicenter Study of Bendamustine Plus Rituximab in Patients with Relapsed Indolent B-Cell and Mantle Cell Non-Hodgkin’s Lymphoma,” 26 <i>J. Clin. Oncol.</i> 4473 (September 20, 2008)
2008	Wolfgang U. Knauf, et al., “Phase III Randomized Study of Bendamustine Compared with Chlorambucil in Previously Untreated Patients with Chronic Lymphocytic Leukemia,” 27 <i>J. Clin. Oncol.</i> 4278 (September 10, 2009)
2009	Wolfgang U. Knauf, et al., “Bendamustine Compared with Chlorambucil in Previously Untreated Patients with Chronic Lymphocytic Leukaemia: Updated Results of a Randomized Phase III Trial,” 159 <i>Brit. J. Hematology</i> 67 (August 4, 2012)

IPR2016-00111 (Paper No. 16)
Patent Owner's Updated Exhibit List

EXHIBIT	DESCRIPTION
2010	Norbert Niederle, et al., "Bendamustine Compared to Fludarabine as Second-Line Treatment in Chronic Lymphocytic Leukemia," <i>92 Ann. Hematology</i> 653 (January 23, 2013)
2011	Teva Pharmaceutical Industries Limited, Form 20-F, 2014
2012	Teva Pharmaceutical Industries Limited, Form 20-F, 2011
2013	Cephalon, Inc., Form 10-K, 2010
2014	Cephalon, Inc., Form 10-K, 2009
2015	Cephalon, Inc., Form 10-K, 2008
2016	Bendamustine, Keating et al., <i>Nature Reviews Drug Discovery</i> 7, 473-474 (June 2008)
2017	<i>Cancer Chemotherapy and Biotherapy: Principles and Practice</i> (Dec. 7, 2011)
2018	CONFIDENTIAL – Agreement between the Parties

Dated: July 26, 2016

Respectfully submitted,

KAYE SCHOLER LLP

/s/ Soumitra Deka

Soumitra (Sam) Deka

(No. 70,252)

soumitra.deka@kayescholer.com

Two Palo Alto Square

3000 El Camino Real, Suite 400

Palo Alto, CA 94306

Tel: (212) 836-8000

Fax: (212) 836-8689

Attorneys for Patent Owner

CERTIFICATION OF SERVICE

The undersigned hereby certifies that the foregoing PATENT OWNER'S
UPDATED EXHIBIT LIST was served electronically via e-mail on this 26th day
of July, 2016, and directed to:

Counsel for Petitioner

Lawrence Sung
Neal Seth
WILEY REIN LLP
nseth@wileyrein.com
lsung@wileyrein.com

WILEY REIN LLP
ATTN: Patent Administration
1776 K Street NW
Washington, DC 20006

Dated: July 26, 2016

KAYE SCHOLER LLP

By /Soumitra Deka #70,252
Soumitra (Sam) Deka
Two Palo Alto Sq.
3000 El Camino Real
Palo Alto, CA 94306